BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 16865242)

  • 1. Raf kinase inhibitor protein is downregulated in hepatocellular carcinoma.
    Schuierer MM; Bataille F; Weiss TS; Hellerbrand C; Bosserhoff AK
    Oncol Rep; 2006 Sep; 16(3):451-6. PubMed ID: 16865242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction in Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines.
    Schuierer MM; Bataille F; Hagan S; Kolch W; Bosserhoff AK
    Cancer Res; 2004 Aug; 64(15):5186-92. PubMed ID: 15289323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.
    Jazirehi AR; Vega MI; Chatterjee D; Goodglick L; Bonavida B
    Cancer Res; 2004 Oct; 64(19):7117-26. PubMed ID: 15466208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Raf kinase inhibitory protein inhibits beta-cell proliferation.
    Zhang L; Fu Z; Binkley C; Giordano T; Burant CF; Logsdon CD; Simeone DM
    Surgery; 2004 Sep; 136(3):708-15. PubMed ID: 15349122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Raf kinase inhibitor protein inhibits cell proliferation but promotes cell migration in rat hepatic stellate cells.
    Ma J; Li F; Liu L; Cui D; Wu X; Jiang X; Jiang H
    Liver Int; 2009 Apr; 29(4):567-74. PubMed ID: 19323783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expression of Raf kinase inhibitor protein and its significance in invasion and metastasis of hepatocellular carcinoma].
    Wu XH; Wang SX; Yang YJ; Li JK; Xu Z; Tang RF
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):358-62. PubMed ID: 21875465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
    Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
    J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of Raf kinase inhibitor protein (RKIP) in health and disease.
    Keller ET; Fu Z; Brennan M
    Biochem Pharmacol; 2004 Sep; 68(6):1049-53. PubMed ID: 15313400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The biology of a prostate cancer metastasis suppressor protein: Raf kinase inhibitor protein.
    Keller ET; Fu Z; Brennan M
    J Cell Biochem; 2005 Feb; 94(2):273-8. PubMed ID: 15565643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Down-regulation of CYLD as a trigger for NF-κB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells.
    Urbanik T; Köhler BC; Boger RJ; Wörns MA; Heeger S; Otto G; Hövelmeyer N; Galle PR; Schuchmann M; Waisman A; Schulze-Bergkamen H
    Int J Oncol; 2011 Jan; 38(1):121-31. PubMed ID: 21109933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leptin induces proliferation and anti-apoptosis in human hepatocarcinoma cells by up-regulating cyclin D1 and down-regulating Bax via a Janus kinase 2-linked pathway.
    Chen C; Chang YC; Liu CL; Liu TP; Chang KJ; Guo IC
    Endocr Relat Cancer; 2007 Jun; 14(2):513-29. PubMed ID: 17639064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison study of the expressions of myristoylated alanine-rich C kinase substrate in hepatocellular carcinoma, liver cirrhosis, chronic hepatitis, and normal liver.
    Masaki T; Tokuda M; Yoshida S; Nakai S; Morishita A; Uchida N; Funaki T; Kita Y; Funakoshi F; Nonomura T; Himoto T; Deguchi A; Kimura Y; Izuishi K; Wakabayashi H; Usuki H; Yoshiji H; Watanabe S; Kurokohchi K; Kuriyama S
    Int J Oncol; 2005 Mar; 26(3):661-71. PubMed ID: 15703821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors.
    Yoshida T; Hisamoto T; Akiba J; Koga H; Nakamura K; Tokunaga Y; Hanada S; Kumemura H; Maeyama M; Harada M; Ogata H; Yano H; Kojiro M; Ueno T; Yoshimura A; Sata M
    Oncogene; 2006 Oct; 25(45):6056-66. PubMed ID: 16652141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone morphogenetic protein 4 is induced in hepatocellular carcinoma by hypoxia and promotes tumour progression.
    Maegdefrau U; Amann T; Winklmeier A; Braig S; Schubert T; Weiss TS; Schardt K; Warnecke C; Hellerbrand C; Bosserhoff AK
    J Pathol; 2009 Aug; 218(4):520-9. PubMed ID: 19431154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raf kinase inhibitor protein regulation of raf and MAPK signaling.
    Hagan S; Garcia R; Dhillon A; Kolch W
    Methods Enzymol; 2006; 407():248-59. PubMed ID: 16757329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of Raf-1 kinase inhibitor protein expression correlates with breast cancer metastasis.
    Hagan S; Al-Mulla F; Mallon E; Oien K; Ferrier R; Gusterson B; García JJ; Kolch W
    Clin Cancer Res; 2005 Oct; 11(20):7392-7. PubMed ID: 16243812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of protein kinase C beta-extracellular signal-regulating kinase 1/2/p38 mitogen-activated protein kinase-heat shock protein 27 activation in hepatocellular carcinoma cell motility and invasion.
    Guo K; Liu Y; Zhou H; Dai Z; Zhang J; Sun R; Chen J; Sun Q; Lu W; Kang X; Chen P
    Cancer Sci; 2008 Mar; 99(3):486-96. PubMed ID: 18167130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of gene expression of ATP-binding cassette protein and tyrosine kinase signaling pathway in patients with hepatocellular carcinoma.
    Hoffmann K; Shibo L; Xiao Z; Longerich T; Büchler MW; Schemmer P
    Anticancer Res; 2011 Nov; 31(11):3883-90. PubMed ID: 22110214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
    Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP.
    Yeung K; Seitz T; Li S; Janosch P; McFerran B; Kaiser C; Fee F; Katsanakis KD; Rose DW; Mischak H; Sedivy JM; Kolch W
    Nature; 1999 Sep; 401(6749):173-7. PubMed ID: 10490027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.